Pegintron market outlook points to steady growth as hepatitis demand persists

The Business Research Company says the global Pegintron market is set for continued expansion through 2035, supported by chronic hepatitis treatment demand, broader use in combination regimens and growth in developing markets. North America is expected to lead in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Pegintron, a pegylated interferon used for hepatitis, remains relevant as chronic viral infections continue to drive demand for treatment options. - The market’s trajectory matters because Pegintron is still used in select patient groups, even as newer antivirals gain share. - The report points to ongoing demand in hospital pharmacies and in combination regimens, which supports continued commercial relevance for the drug.

What happened: - The Business Research Company released its Pegintron Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the Pegintron market is evolving steadily and is expected to expand further through 2035. - The report centers on peginterferon alfa-2b, sold as Pegintron, which is used mainly for chronic hepatitis C and some forms of hepatitis B. - The company also published a free sample report and the full market report online: Download the free sample and View the full report.

The details: - Pegintron works by attaching polyethylene glycol to interferon, which extends the drug’s activity in the body. - The drug stimulates the immune system to fight viral infections and aims to reduce viral load and improve liver function. - The report says market growth has been supported by proven safety and efficacy, broad physician acceptance, hospital pharmacy availability and the global hepatitis burden. - Future growth is expected to come from specialized demand, continued use alongside newer antiviral therapies, personalized medicine, broader access in developing countries and ongoing clinical investigation into interferon. - Emerging trends include greater focus on pegylated interferon therapies, a gradual decline in first-line use, continued use in select patient groups, immune-response modulation and efforts to improve dosing and administration. - The report identifies rising hepatitis C prevalence as a key driver of demand. - The European Centre for Disease Prevention and Control reported 28,622 hepatitis C cases across 29 EU/EEA countries in 2023, a rate of 7.4 per 100,000 people. - The report also points to rising chronic disease prevalence as a growth catalyst. - The World Health Organization reported 41 million global deaths annually from non-communicable diseases in 2023, representing 74% of all deaths worldwide. - The report says biopharmaceutical growth is also supporting the market. - A 2023/2024 UK Office for Life Sciences report found 32% of biopharmaceutical companies focus primarily on research and development, compared with 10% in the medical technology sector. - Regional coverage in the report includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America is projected to hold the largest global market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The 2026 report format includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis.

Between the lines: - The report signals a mature market that is not disappearing, but shifting from broad first-line use toward narrower clinical niches. - The emphasis on combination therapy, dosing optimization and immune modulation suggests Pegintron’s role is becoming more specialized rather than abandoned. - The regional growth split suggests demand is being pulled by established treatment markets in North America and faster adoption or access gains in Asia-Pacific.

What's next: - The report expects continued market expansion through 2035 as hepatitis treatment needs persist and access widens in developing markets. - Ongoing clinical research into interferon may help define where Pegintron fits in future treatment protocols. - The company is also marketing expanded strategic intelligence tools in its 2026 reports, including dashboards, scoring matrices and hotspot analysis.

The bottom line: - Pegintron appears to be moving from a broad hepatitis therapy to a more targeted, still-relevant market with growth tied to chronic disease burden, combination use and regional expansion.